Abstract

Pancreas stem cells are a potential source of insulin-producing β cells for the therapy of diabetes. In adult tissues the ‘side population’ (SP) of cells that effluxes the DNA binding dye Hoechst 33342 through ATP-binding cassette transporters has stem cell properties. We hypothesised therefore that the SP would expand in response to β cell injury and give rise to functional β cells. SP cells were flow sorted from dissociated pancreas cells of adult mice, analysed for phenotype and cultured with growth promoting and differentiation factors before analysis for hormone expression and glucose-stimulated insulin secretion. SP cell number and colony forming potential (CFP) increased significantly in models of type diabetes, and after partial pancreatectomy, in the absence of hyperglycaemia. SP cells, ∼1% of total pancreas cells at 1 week of age, were enriched >10-fold for CFP compared to non-SP cells. Freshly isolated SP cells contained no insulin protein or RNA but expressed the homeobox transcription factor Pdx1 required for pancreas development and β cell function. Pdx1, along with surface expression of CD326 (Ep-Cam), was a marker of the colony forming and proliferation potential of SP cells. In serum-free medium with defined factors, SP cells proliferated and differentiated into islet hormone-expressing cells that secreted insulin in response to glucose. Insulin expression was maintained when tissue was transplanted within vascularised chambers into diabetic mice. SP cells in the adult pancreas expand in response to β cell injury and are a source of β cell progenitors with potential for the treatment of diabetes.

Highlights

  • Loss of insulin production in type 1 diabetes (T1D) following autoimmune destruction of b cells in the islets of the pancreas requires life-long treatment with insulin injections

  • If side population’ (SP) cells have the capacity to develop into insulin-secreting cells we hypothesised that they would expand in response to b cell or pancreatic injury

  • We quantified the SP in four models of diabetes, as well as in response to partial pancreatectomy. The latter is insufficient to cause diabetes, excluding the possibility that an effect is due to hyperglycaemia

Read more

Summary

Introduction

Loss of insulin production in type 1 diabetes (T1D) following autoimmune destruction of b cells in the islets of the pancreas requires life-long treatment with insulin injections. Insulin treatment is demanding and rarely achieves physiologic control of blood glucose. Transplantation of the pancreas or pancreatic islets can restore near-normal glucose homeostasis, but is technically demanding, expensive and limited by a shortage of donor tissue, and not all recipients achieve insulin-independence [1,2]. There is a strong imperative to derive renewable sources of insulin-producing cells to ‘cure’ T1D. Defined growthdifferentiation conditions have been used to coax development of embryonic stem cells (ESCs) through definitive endoderm and pancreatic endoderm to insulin-producing endocrine cells [3,4]. Chromosomal instability in ESCs and their potential for oncogenesis in vivo remain a concern [5,6]

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call